Mounjaro Alternative for $125/Month: Same Tirzepatide, Fraction of the Price
Mounjaro costs $1,000–$1,300/month without insurance. Compounded tirzepatide contains the same dual GIP/GLP-1 agonist and is available through Trimi for $125/month. Here is what you need to know.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This guide explains Mounjaro's pricing, tirzepatide's dual-mechanism advantage, and how compounded tirzepatide delivers the same results for $125/month.
Quick links: Tirzepatide treatment, Zepbound alternative guide, and affordable weight loss shots.
More on Affordable Tirzepatide Access
Cheap Zepbound Alternative 2026
Compounded tirzepatide as a Zepbound alternative from $125/month.
Ozempic Alternative for $99/Month
Compounded semaglutide versus Ozempic — the cost breakdown.
Why Is Compounded Semaglutide So Cheap?
The compounding economics that make lower prices possible.
Start Semaglutide This Week
Quick-start guide from signup to first injection.
Mounjaro: The Most Effective GLP-1 You Cannot Afford
Tirzepatide is the most effective prescription weight loss medication available in 2026. Approved by the FDA for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound, tirzepatide works through a mechanism no prior medication has used: simultaneous activation of both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors.
The clinical results are remarkable. In the SURMOUNT-1 trial — the landmark study for tirzepatide in obesity — patients taking the maximum 15mg dose lost an average of 22.5% of their body weight over 72 weeks. At 52 pounds of weight loss for a 230-pound person, these are results historically associated with bariatric surgery. Even at the lowest therapeutic dose of 5mg, average weight loss was 15%.
The problem is price. Mounjaro's list price is approximately $1,069 per month in 2026. Zepbound — the same tirzepatide, rebranded for the obesity indication — lists at a similar price. Without insurance that specifically covers these medications for obesity, cost is an insurmountable barrier for most patients.
Price comparison: Mounjaro/Zepbound list price approximately $1,069/month. Compounded tirzepatide through Trimi: $125/month — a saving of approximately $944 per month, or over $11,000 per year.
Why Tirzepatide's Dual Mechanism Produces Superior Results
To understand why tirzepatide outperforms semaglutide, it helps to understand what GIP does. GLP-1 receptor agonists like semaglutide are effective because GLP-1 activation reduces appetite and slows gastric emptying. But GIP receptors in the brain and fat tissue appear to work synergistically with GLP-1 signaling in ways that produce additional weight loss beyond what GLP-1 activation alone achieves.
Tirzepatide was engineered specifically to activate both receptor types with a single weekly injection. The result is an additive (some researchers argue synergistic) effect on appetite suppression, energy expenditure, and metabolic regulation. This is why SURMOUNT-5, a head-to-head trial of tirzepatide versus semaglutide for obesity, found that tirzepatide produced significantly greater weight loss — approximately 47% greater absolute weight reduction.
This clinical advantage is pharmacological — it is a property of the tirzepatide molecule itself. Compounded tirzepatide contains the same molecule and activates the same dual receptor pathway. The $125 price does not diminish the dual GIP/GLP-1 mechanism. The clinical advantage of tirzepatide over semaglutide is fully available in the compounded form.
Compounded Tirzepatide vs Mounjaro: What Is Actually Different
Mounjaro and compounded tirzepatide both deliver tirzepatide via weekly subcutaneous injection. Here is what is genuinely different and what is not:
| Feature | Mounjaro | Compounded Tirzepatide (Trimi) |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide (identical) |
| Mechanism of action | Dual GIP/GLP-1 agonist | Dual GIP/GLP-1 agonist (identical) |
| Monthly cost | ~$1,069 list price | $125/month all-inclusive |
| Delivery device | KwikPen auto-injector | Vial + syringe (standard subcutaneous) |
| Insurance required | Yes for coverage; full price without | No insurance required |
| FDA approval | Mounjaro brand approved | Compounded under 503A/503B regulations |
| Dose options | 2.5mg to 15mg weekly | 2.5mg to 15mg weekly (same schedule) |
| Quality testing | Manufacturer QC | Third-party batch testing (pharmacy) |
The delivery device difference is worth noting. Mounjaro uses an auto-injector that conceals the needle and makes self-injection more straightforward for needle-hesitant patients. Compounded tirzepatide uses a standard vial and syringe, which is the same system used by tens of millions of insulin-dependent patients worldwide. Most patients adapt quickly. Trimi provides detailed injection instructions and patients with injection concerns can consult their provider.
Trimi's $125/Month Tirzepatide Program
Trimi offers compounded tirzepatide at $125 per month through a fully online telehealth process. The program includes the clinical consultation, medication, and ongoing provider access for dose adjustments and side effect management. Here is the full process:
Online health assessment
A 10 to 15 minute questionnaire covering your weight history, medical conditions, current medications, and any contraindications to tirzepatide. Personal history of medullary thyroid carcinoma, MEN2, or pancreatitis are evaluated at this stage.
Physician review within 24 hours
A board-certified Trimi provider reviews your submission and determines eligibility. Standard criteria are a BMI of 30 or higher, or BMI 27 or higher with a weight-related comorbidity.
Prescription to compounding pharmacy
Approved patients receive a prescription for compounded tirzepatide at 2.5mg/week starting dose. The prescription goes to a PCAB-accredited 503B compounding facility.
Medication shipped within 5–7 business days
Your compounded tirzepatide arrives in temperature-controlled packaging with syringes, alcohol swabs, sharps disposal instructions, and a dosing guide.
Monthly dose management
Refills ship automatically each month. Your provider manages dose escalation according to your response and tolerance, progressing toward the maximum 15mg dose as appropriate.
Side Effects of Tirzepatide
Tirzepatide's side effect profile is similar to semaglutide's, reflecting their shared GLP-1 mechanism, with some differences related to the additional GIP activation. The most common side effects are gastrointestinal and typically occur during dose escalation:
Nausea
Most common, typically mild to moderate, most pronounced in weeks 1–4 at each new dose. Usually improves within 2–4 weeks.
Constipation
More common with tirzepatide than semaglutide based on trial data. Adequate hydration and fiber intake help significantly.
Diarrhea
Less common than constipation but occurs in some patients, particularly during early escalation phases.
Vomiting
Occurs in a minority of patients. Usually associated with eating too quickly or too large portions as appetite suppression intensifies.
Injection site reactions
Mild redness or irritation at the injection site, typically resolving within 24 hours. Rotating injection sites reduces this.
Serious side effects — including pancreatitis, gallbladder disease, and the theoretical risk of thyroid C-cell tumors observed in rodent studies — are the same for compounded and brand-name tirzepatide. Your Trimi provider discusses these risks during your consultation and monitors for warning signs throughout treatment. For a comprehensive overview of GLP-1 side effects and how to manage them, see our dedicated guide.
Tirzepatide vs Semaglutide: Which Should You Choose?
Both compounded tirzepatide ($125/month) and compounded semaglutide ($99/month) are available through Trimi. The choice between them depends on several factors:
Choose tirzepatide ($125/mo) if:
- Maximum weight loss is the primary goal
- You have type 2 diabetes (tirzepatide provides additional glycemic benefit)
- You have tried semaglutide and want stronger results
- You are comfortable with the additional $26/month cost
Choose semaglutide ($99/mo) if:
- Cost minimization is the priority
- You have already responded well to semaglutide
- You prefer the most extensively studied GLP-1 option
- Your provider recommends semaglutide as first-line
For more detail on the comparison, see our guide to semaglutide versus tirzepatide. Both are available through Trimi, and your provider can help you evaluate the best option for your specific situation during the consultation.
Frequently Asked Questions
Is compounded tirzepatide the same as Mounjaro?
Compounded tirzepatide contains the identical active molecule — tirzepatide — as Mounjaro. Both work by activating both GIP receptors and GLP-1 receptors simultaneously, which is why tirzepatide produces greater weight loss than semaglutide alone. The difference between Mounjaro and compounded tirzepatide is not in the active molecule but in the manufacturer, delivery device, and pricing structure. Mounjaro comes from Eli Lilly in a proprietary auto-injector at $1,000 to $1,300 per month. Compounded tirzepatide is available through Trimi at $125 per month.
How much weight can I lose with compounded tirzepatide?
The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that tirzepatide at the maximum 15mg dose produced average weight loss of 22.5% of body weight over 72 weeks — about 52 pounds for someone starting at 230 pounds. Even at the 5mg dose, average weight loss was 15%. These results exceed what semaglutide produces, largely because tirzepatide activates both GIP and GLP-1 receptors. Compounded tirzepatide contains the same active molecule and is expected to produce equivalent results.
Why is Mounjaro so expensive without insurance?
Mounjaro's list price of approximately $1,069 per month reflects Eli Lilly's research and development costs for tirzepatide, including the dual GIP/GLP-1 mechanism that required significant innovation to develop, plus patent exclusivity, FDA approval expenses, and supply chain markups. The KwikPen auto-injector device adds further cost. Compounded tirzepatide removes the brand premium, device cost, and distribution markups, making the same molecule available at a fraction of the price.
Is tirzepatide better than semaglutide?
Head-to-head data consistently shows tirzepatide producing greater weight loss than semaglutide. The SURMOUNT-5 trial directly compared tirzepatide and semaglutide for obesity treatment and found significantly greater weight loss with tirzepatide. The dual GIP and GLP-1 receptor activation appears to produce synergistic effects beyond GLP-1 activation alone. However, both medications produce clinically meaningful weight loss, and the best choice depends on individual patient factors, tolerance, and goals. Trimi offers both compounded semaglutide at $99 and compounded tirzepatide at $125.
Can I get compounded tirzepatide if I have been denied Mounjaro coverage?
Yes. Insurance denials for Mounjaro do not affect your access to compounded tirzepatide through Trimi. The two pathways are completely independent. Trimi's telehealth process requires no insurance, no prior authorization, and no step therapy. You complete an online assessment, a physician reviews it, and if you qualify, your medication ships from an accredited compounding pharmacy at $125 per month.
What doses does compounded tirzepatide come in?
Compounded tirzepatide is available at doses that match the standard Mounjaro titration schedule: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg per week. Your Trimi provider will prescribe the starting dose (typically 2.5mg) and escalate based on your tolerance and progress. Patients transitioning from Mounjaro continue at their current dose without restarting the titration schedule.
How does Trimi's compounded tirzepatide compare on quality to Mounjaro?
Quality of compounded tirzepatide depends on the compounding pharmacy. Trimi partners exclusively with PCAB-accredited and FDA-registered 503B outsourcing facilities that perform third-party testing for potency, purity, and sterility on every batch. These facilities operate under the same cGMP standards applied to pharmaceutical manufacturing. The active tirzepatide molecule is sourced from verified API suppliers. The difference from Mounjaro is commercial, not quality-related: no brand markup, no proprietary device, and no supply chain premium.
Sources & References
- Jastreboff AM et al. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. NEJM, 2022.
- Garvey WT et al. SURMOUNT-2: Tirzepatide for obesity with type 2 diabetes. NEJM, 2022.
- Mounjaro FDA prescribing information, 2022.
- Wilding JPH et al. STEP 1: Semaglutide for weight management. NEJM, 2021.
- FDA: Compounding and FDA — Questions and Answers.
- NABP compounding pharmacy accreditation standards.
- NIDDK: Prescription medications to treat overweight and obesity.
- FDA drug shortage database.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Trimi provides compounded GLP-1 medications through licensed telehealth physicians. Individual results vary and are not guaranteed.